Literature DB >> 26040271

Synthesis and Biological Evaluation of Novel Aryl-2H-pyrazole Derivatives as Potent Non-purine Xanthine Oxidase Inhibitors.

Zhi-Gang Sun1, Xiao-Jing Zhou, Ming-Li Zhu, Wen-Ze Ding, Zhen Li, Hai-Liang Zhu.   

Abstract

A series of aryl-2H-pyrazole derivatives were synthesized and evaluated for inhibitory activity against xanthine oxidase in vitro as potent xanthine oxidase inhibitors. Among them, 2 aryl-2H-pyrazole derivatives showed significant inhibitory activities against xanthine oxidase. Compound 19 emerged as the most potent xanthine oxidase inhibitor (IC50=9.8 µM) in comparison with allopurinol (IC50=9.5 µM). The docking study revealed that compound 19 might have strong interactions with the active site of xanthine oxidase. This compound is thus a new candidate for further development for the treatment of gout.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26040271     DOI: 10.1248/cpb.c15-00282

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


  2 in total

1.  Therapeutic effects and mechanisms of N-(9,10-anthraquinone-2-ylcarbonyl) xanthine oxidase inhibitors on hyperuricemia.

Authors:  Tianshu Gao; Jin Xu; Yuxiao Xiao; Jiaqi Li; Weifeng Hu; Xiaoyu Su; Xudong Shen; Wan Yu; Zhen Chen; Baosheng Huang; Honglei Li; Xing Wang
Journal:  Front Pharmacol       Date:  2022-09-02       Impact factor: 5.988

Review 2.  Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview.

Authors:  Changyi Chen; Jian-Ming Lü; Qizhi Yao
Journal:  Med Sci Monit       Date:  2016-07-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.